A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: DRUG: AZD9833
Sponsor: AstraZeneca